Sugi Predict

Sugi Predict / Compounds / SCHEMBL18908294

SCHEMBL18908294

SCHEMBL18908294

CCCC(=O)OC[C@H](OCC(C)COCc1ccccc1)c1cc(F)ccc1OC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ PTGDR2 Q9Y5Y4 1/20 0.37
▸ CA1 P00915 2/20 0.37
▸ CA2 P00918 2/20 0.37
▸ ACHE P22303 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ SLC6A9 P48067 1/20 0.35
▸ SLC6A5 Q9Y345 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ MC4R P32245 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ HPGD P15428 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ ALOX5 P09917 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18908287 0.86 SMN1; SMN2 (0.34) SMN1; SMN2LMNA
SCHEMBL18908273 0.83 ALDH1A1 (0.39) FFAR1FFAR4PTGDR2CA1CA2
SCHEMBL18908296 0.83 ALDH1A1 (0.39) FFAR1FFAR4PTGDR2CA1CA2
SCHEMBL18821425 0.80 SLC6A9 (0.42) FFAR1FFAR4ALDH1A1SLC6A9SLC6A5
SCHEMBL18908199 0.79 PTGDR2 (0.36) FFAR1FFAR4PTGDR2CA1CA2
SCHEMBL18972304 0.79 SLC6A9 (0.43) FFAR1FFAR4SLC6A9SLC6A5SMN1; SMN2
SCHEMBL18907710 0.78 SLC6A9 (0.42) FFAR1FFAR4SLC6A9SLC6A5CYP2C19
SCHEMBL18914272 0.78 ALOX15 (0.36) FFAR1FFAR4
SCHEMBL18894946 0.77 KDM4E (0.37) FFAR1FFAR4MAPK1
SCHEMBL18908502 0.77 TAS1R3 (0.33) FFAR1FFAR4ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10800791-B2 Triazole ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2020-10-13 — — US disclosed
US-20190241582-A1 Triazole ACC inhibitors and uses thereof Nimbus Apollo, Inc. 2019-08-08 — — US disclosed
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 — — US disclosed
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2017-06-15 — — US disclosed
WO-2017091617-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC (US) 2017-06-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241582-A1 Triazole ACC inhibitors and uses thereof ACACA, ACACB, ACAT1 FFAR1 2886/4885FFAR4 2952/4885PTGDR2 3983/4885
US-10800791-B2 Triazole ACC inhibitors and uses thereof ACACA, ACACB, ACAT1 FFAR1 2886/4885FFAR4 2952/4885PTGDR2 3983/4885
US-20170166584-A1 TRIAZOLE ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT1 FFAR1 2886/4885FFAR4 2952/4885PTGDR2 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.